Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
March 3, 2016 4:01 PM ESTProTmune Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016
Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016
Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16
SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2015.
During this... More
